BioSpace News Archive

Aquestive Therapeutics, Inc. today announced positive topline data from its first-in-human Phase 1 PK study of AQST-109 sublingual film for the delivery of epinephrine in the emergency treatment of allergic reactions including anaphylaxis.

OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to initiate a Phase 2a trial for SCN9A antisense pain killer OLP-1002 in Australia.

Jaguar Health, Inc the today announced that the legally required “Golden Powers” process was successfully completed and that the merger of Jaguar’s Italian subsidiary Napo EU S.p.A. and Dragon SPAC S.p.A. is expected to be effective within a week.

Tremeau Pharmaceuticals today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/240,446. Once issued, the patent will provide composition of matter patent protection for Tremeau’s novel deuterium-enriched etoricoxib compound, TRM-362 (d3-etoricoxib), through at least April 2041.

Nereid Therapeutics, a company discovering new disease treatments by applying pioneering research and technologies in biomolecular condensates, announces the appointment of Laura L. Forese, M.D., MPH, and Rupert Vessey, FRCP, Ph.D., to its Board of Directors.

Advarra, the market leader in regulatory review solutions, research quality and compliance consulting services and clinical research technology solutions, announced today the launch of Site IQ™ to enable faster study startup.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), today announced that it will host a key opinion leader (KOL) webinar on the compelling need to salvage central venous catheters in patients with central line associated blood stream infections (CLABSI) on Thursday, November 11, 2021 at 11:30am Eastern Time.

Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Dr. Doug Girgenti as Vice President of Drug Development, effective today.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that a scientific presentation on pimavanserin for the treatment of hallucinations and delusions in patients with Parkinson’s disease dementia will be shared at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference.

Inspiritol, Inc., a virtual pharmaceutical start-up filed a response with the FDA as part of their Investigational New Drug Application process for Inspiritol, a novel treatment for COVID-19, Long-COVID, and ME/CFS (Myalgic encephalomyelitis/chronic fatigue).